<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic stem cell transplantation (SCT) has the potential to cure patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), but a number of prognostic factors can influence the outcome of transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>At present, no transplantation-specific risk score exists for this patient population </plain></SENT>
<SENT sid="2" pm="."><plain>We propose a simple scoring system for patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, based on a retrospective analysis of 445 patients undergoing SCT at our institution (divided into training and validation subsets) </plain></SENT>
<SENT sid="3" pm="."><plain>The score depends on 5 variables: age, disease, stage at transplantation, cytogenetics, and pretransplantation ferritin </plain></SENT>
<SENT sid="4" pm="."><plain>It divides patients into 3 groups of comparable size, with 5-year overall survival (OS) of 56% (low risk), 22% (intermediate risk), and 5% (high risk) </plain></SENT>
<SENT sid="5" pm="."><plain>This prognostic score could be useful in making treatment decisions for individual patients, in stratifying patients entering clinical trials, and in adjusting transplantation outcomes across centers under the new federal reporting rules </plain></SENT>
</text></document>